A hallmark feature of glioblastoma is its strong self-renewal potential and immature differentiation state, which contributes to its plasticity and therapeutic resistance. Here, integrated genomic and biological analyses identified PLAGL2 as a potent protooncogene targeted for amplification/gain in malignant gliomas. Enhanced PLAGL2 expression strongly suppresses neural stem cell (NSC) and glioma-initiating cell differentiation while promoting their self-renewal capacity upon differentiation induction. Transcriptome analysis revealed that these differentiation-suppressive activities are attributable in part to PLAGL2 modulation of Wnt/b-catenin signaling. Inhibition of Wnt signaling partially restores PLAGL2-expressing NSC differentiation capacity. The identification of PLAGL2 as a glioma oncogene highlights the importance of a growing class of cancer genes functioning to impart stem cell-like characteristics in malignant cells.
INTRODUCTION
Malignant gliomas, the most common primary brain tumors in adults, are associated with an extremely high rate of morbidity and mortality (Furnari et al., 2007) . In its most aggressive form, glioblastoma (GBM) has an average survival of 1 year and characteristic features of diffuse invasion, intense apoptosis resistance and necrosis, robust angiogenesis, and a varied so-called multiforme histological profile suggestive of developmental plasticity. It is well known that malignant gliomas are heterogeneous both in their cell composition and in the relative abundance of cells capable of propagating tumor cells, albeit the underlying mechanism remains poorly understood (Furnari et al., 2007; Rich and Eyler, 2008; Vescovi et al., 2006) . The recent identification of a subpopulation of tumor cells, designated as glioma stem cell or glioma-initiating cells (GICs), with strong tumor repopulating potential has illuminated a potential basis for the intense plasticity and heterogeneous nature of this disease (Bao et al., 2006; Calabrese et al., 2007; Hemmati et al., 2003; Lee et al., 2006; Piccirillo et al., 2006; Singh et al., 2004; Son et al., 2009 ).
Significance
The identification of tumor-initiating cells with stem cell-like properties in diverse cancers, including glioblastoma (GBM), represents an important conceptual advance with therapeutic implications. There is increasing recognition that elucidation of the molecular factors governing self-renewal and differentiation of the glioma-initiating cells will advance our understanding of glioma pathogenesis and biology. Such insights-at the intersection of stem cell and cancer biology-may provide new points for therapeutic intervention. Here, the identification of PLAGL2 as an amplified gene in human GBM with oncogenic activity and capacity to regulate Wnt signaling highlights the contribution of differentiation defect in gliomagenesis and points to differentiation pathways as promising targets for malignant glioma treatment.
These GICs share certain features of normal neural stem cells (NSCs) including the expression of neural progenitor markers, long term self-renewal capacity, and partial multi-lineage differentiation potential. However, unlike the normal NSCs that follow the developmental hierarchy and differentiate inevitably into replication-arrested mature cells (Alvarez-Buylla et al., 2001; Gage, 2000; Temple, 2001) , the GICs exhibit anomalous developmental programs that enable escape from terminal differentiation cues and preserve self-renewal state (Jackson et al., 2006; Ricci-Vitiani et al., 2007; Sanai et al., 2005) . Notably, restoration of their differentiation capacities can drastically reduce GIC tumorigenic potential, supporting the idea that maintenance of an aberrant differentiation state can contribute to glioma pathogenesis (Jackson et al., 2006; Lee et al., 2008; Ricci-Vitiani et al., 2007; Zheng et al., 2008) .
GBM possesses a highly rearranged genome. High-resolution genome-scale analysis of such has uncovered myriad somatic alterations on the genomic and epigenetic levels, which presumably harbor GBM-related oncogenes or tumor suppressors. To identify these events, we previously had performed high resolution, oligo-based array comparative genomic hybridization (CGH) profiling of 18 pathologically verified primary GBM specimens and 20 established glioma cell lines (Wiedemeyer et al., 2008) . Using the nonheuristic genome topography scan (GTS) algorithm, we further identified and ranked the signature genomic events known previously for GBM (e.g., EGFR amplification or CDKN2A deletion) as well as many previously uncharacterized alterations based on their amplitude, width, and recurrence of a copy number alteration (Wiedemeyer et al., 2008 ).
Here we carried an in-depth study on one of the uncharacterized amplified/gained regions that is localized at chromosome 20q11.21.
RESULTS

PLAGL2
Is Targeted for Amplification and Overexpression GTS analysis of the array CGH profiles of 18 pathologically verified primary GBM specimens and 20 glioma cell lines identified chromosome 20q11.21 as a region of amplification or gain ( Figure 1A ; Wiedemeyer et al., 2008) . These profiles delimited a 500 Kb minimal common region of amplification encompassing seven characterized genes (HCK, TM9SF4, TSPYL3, PLAGL2, POFUT1, ASXL1, and KIF3B) , two conserved open reading frames (ORFs) (c20orf120 and c20orf112), and one pseudogene (RPL24P1) ( Figure 1B ). Regional amplifications/gains were further confirmed in the primary tumor (#G328) and cell lines (LN229) by fluorescence in situ hybridization (FISH) using a probe within the 20q11.21 amplicon ( Figure 1C ). Subsequent analysis of the TCGA data confirmed increased copy number of a broad region at 20q11.21 in 35 of 238 (14.7%) human GBM array CGH profiles (http://tcga-data.nci.nih.gov/tcga/findArchives.htm). The potential cancer relevance of this region was further suggested by its amplification/gain in approximately 40% of primary colorectal cancer specimens and cells lines ( Figure S1 , available online; Martin et al., 2007) .
To determine the oncogenic potential of all nine genes residing within this amplicon, we first assessed their ability to promote anchorage-independent growth. In these studies, we used freshly isolated primary murine astrocytes doubly null for Ink4a/Arf and shown as mean ± SD from duplicate cultures of three independent experiments. **p < 0.001 by two-tail t test.
(E) PLAGL2 showed copy number-driven expression in the GBM specimen with 20q11.21 amplification by qRT-PCR. Results are normalized with b-actin expression and shown as mean ± SD. Data are from two independent experiments with triplicates. **p < 0.001 by two-tail t test. See also Figure S1 .
Pten, two signature mutations present in human primary GBM (Cancer Genomes Atlas Research Network, 2008; Parsons et al., 2008) . Notably, these Ink4a/Arf À/À Pten À/À astrocytes do not exhibit anchorage-independent growth unless transduced with additional oncogenes such as the mutant epidermal growth factor receptor EGFRvIII (data not shown). In this ''sensitized'' glioma-relevant background, the above nine ORFs were placed in the pLenti6-V5-DEST expression vector and introduced individually into the Ink4a/Arf À/À Pten À/À astrocytes. Of the nine cancer gene candidates, only PLAGL2 induced colony formation in the semisolid media ( Figure 1D ). Consistent with PLAGL2 as the target in this amplicon, quantitative real-time reverse transcriptase PCR (qRT-PCR) revealed that PLAGL2 showed gene copy number-driven expression in the primary GBM specimen (#G328) with the 20q11.21 amplification ( Figure 1E ). Together, these data suggest that PLAGL2 functions as an oncogene that is targeted for amplification/gain and overexpression in a subset of human GBM and colorectal cancer cases.
PLAGL2 Promotes Cell Transformation In Vitro and Tumorigenesis
In Vivo PLAGL2 (pleiomorphic adenoma gene like 2), a putative C 2 H 2 zinc finger transcription factor, was initially identified through structural homology to its family member PLAG1, a protooncogene frequently rearranged and overexpressed in pleiomorphic salivary gland adenomas and lipoblastomas (Hensen et al., 2002; Kas et al., 1997 Kas et al., , 1998 . Aberrant PLAGL2 expression has recently been implicated in human acute myeloid leukemia (Landrette et al., 2005) . However, the biological functions of PLAGL2, including whether and how it is involved in tumorigenesis, still remain largely unknown. To substantiate the cancer relevance of PLAGL2, we assayed the oncogenic activity of PLAGL2 in several cell-based systems using both gain-and loss-of-function strategies. Consistent with the murine Ink4a/ Arf À/À Pten À/À astrocytes findings, enforced PLAGL2 expression also conferred markedly increased anchorage-independent growth of murine p53 À/À astrocytes ( Figure S2A ) and human glioma cell lines including LN215, A172, Hs683, LNZ308, SF767, and U343 ( Figure 2A and Figure S2A ). In addition, we assessed the impact of PLAGL2 on invasive activity, a hallmark feature of malignant gliomas (Furnari et al., 2007 Figures 2D and  2E ). Of note, suppressing PLAGL2 expression in the LN319 glioma line lacking 20q11.21 amplification and with low PLAGL2 expression failed to impact on anchorage-independent growth ( Figure 2F ), suggesting that PLAGL2 may serve a tumor maintenance role in those gliomas with PLAGL2 gene amplification and high expression.
In line with the colorectal cancer genomic observation, PLAGL2-expressing immortalized rat intestinal epithelial cells (IEC6) exhibited oncogenic properties of (a) growth in an anchorage-independent manner ( Figure S2D ), (b) anoikis resistance on ultra-low cluster plates ( Figure S2E ), and (c) robust tumor growth with metastatic potential within 5 weeks after tail vein injection. In contrast, IEC6 vector control cells failed to produce illness within 3 months of observation ( Figure S2F ). On the basis of these functional studies, we conclude that PLAGL2 is a potent oncogene that is targeted for amplification/gain in a subset of colorectal cancers.
PLAGL2 Promotes Renewal of NSC/Progenitor Cells by Inhibiting Their Differentiation
While enforced PLAGL2 expression in human LN215 glioma cells or primary mouse Ink4a/Arf À/À Pten À/À astrocytes had a notably minimal impact on cellular proliferation, these cells adopted a rounded, less attached, refractile appearance reminiscent of stem/progenitor cells ( Figure S3 ). Correspondingly, these PLAGL2-expressing LN215 cells showed increased expression of the neural stem/progenitor marker Nestin ( Figure S3C ). These findings prompted us to speculate that PLAGL2 may exert its oncogenic impact in part via promoting a stem/progenitor celllike state. To test this hypothesis, we first used murine p53
NSCs as a model system as it affords a primary cell system and allows for analysis in the context of p53 mutation, one of the most frequent alterations in human primary GBM (Cancer Genomes Atlas Research Network, 2008; Parsons et al., 2008) . This p53 À/À NSC model system (and confirmatory studies in wild-type as well as Ink4a/Arf À/À Pten À/À NSCs) was used to explore PLAGL2-directed cellular and molecular activities analogous to those of our previous studies .
When maintained in the serum-free NSC proliferation media supplemented with growth factors EGF and bFGF, both vector control and PlagL2-expressing cells registered roughly the same NSC/progenitor cell marker patterns such as Nestin expression and showed minimal differences in proliferation as measured by BrdU incorporation rate (data not shown). Upon exposure to differentiation media (neural basal media with 1% fetal bovine serum), as expected, the p53 À/À NSC vector control cultures rapidly adopted a flattened cell morphology, drastically diminished Nestin expression, and reciprocally increased GFAP (astrocytic marker) or Tuj1 (early neuronal lineage marker) positive staining. In contrast, PlagL2-expressing p53 À/À NSCs retained their stem/progenitor-like morphology and showed feeble expression of mature lineage markers; 70% of PlagL2-expressing cells retained Nestin expression compared with 5% of control cells (Figures 3A and 3B) . Additionally, we failed to observe cell-cycle exit that accompanies differentiation in the PlagL2-expressing cells as evidenced by their robust BrdU incorporation following either a 3 or 24 hr BrdU pulse (3 hr: 1.6 ± 1.1% versus 15.6 ± 5.0%; 24 hr: 1.5 ± 1.6% versus 84.0 ± 6.6%) ( Figure 3C , p < 0.001). Similar results were also observed using wild-type and Ink4a/Arf À/À Pten À/À mouse NSC cultures (Figures S4A and S4B) .
To confirm further the impaired differentiation phenotype, we used additional differentiation protocols. We first used the bone morphogenetic protein (BMP)-mediated differentiation assay, which is known for its function to activate SMAD1/5/8 and elicit astroglial differentiation of NSC cultures (Lim et al., 2000; Panchision and McKay, 2002) . As expected, BMP2 treatment arrested cell proliferation and stimulated rapid differentiation of the majority of vector control p53 À/À NSCs (77%-80%)
into GFAP-and S-100-positive astroglial lineage cells ( Figures  4A and 4B ); in contrast, over 70% of PlagL2-expressing NSCs retained strong Nestin expression and showed minimal increase of GFAP-and S-100-positive cells. Accordingly, compared to 4% of vector control cells, which incorporated BrdU following BMP treatment, 61% of PlagL2-expressing cells were stained for BrdU ( Figure 4C ). Analogous differentiation findings were obtained for p53 À/À NSC cultures maintained in neural basal media without growth factors ( Figure S4C ). In addition, we confirmed that BMP2 induced strong activation of SMAD1/5/8 components in both vector control and PlagL2-expressing NSCs ( Figure 4D ), indicating the impaired differentiation phenotype is not attributable to suboptimal activation of the BMP signaling pathway in the PlagL2-expressing NSCs. Progressive differentiation of normal stem/progenitor cells is associated with loss of self-renewal capacity, while cancer cells with high tumorigenic potential typically exhibit strong selfrenewal activity with impaired differentiation (Beachy et al., 2004; Buick et al., 1979; Dick, 2008; Reya et al., 2001; Sanai et al., 2005) . We thus tested whether PlagL2 also affects NSC self-renewal activity as measured by neurosphere formation. When cultured at low density (100 cells/ml) in the NSC proliferation medium with EGF and bFGF, the PlagL2-expressing p53 À/À NSCs yielded only slightly more multipotent neurospheres (17.0 ± 3.7% for PLAGL2-expressing NSCs versus 13.8 ± 3.1% for vector control NSCs; p = 0.032) and modestly higher proliferation rates to those of control p53 À/À NSCs (data not shown).
Following BMP2 treatment, while less than 1% of vector control p53 À/À NSCs formed neurospheres, PlagL2-expressing p53
NSCs readily formed neurospheres (0.65 ± 0.7% versus 12.8 ± 4.1%; p < 0.001) ( Figure 4E ). Together, these data establish that enforced PlagL2 expression impedes NSC differentiation and preserves their stem cell features such as self-renewal potential and proliferation under differentiation induction.
PLAGL2 Promotes Gliomagenesis and Maintenance of GIC ''Stemness'' upon Differentiation
The impact of PLAGL2 on NSC renewal and differentiation, coupled with its transforming activity on primary astrocytes as Representative immunofluorescence staining of empty vector control and PlagL2-expressing NSCs cultured in the presence of BMP2 (50 ng/ml) for 5 days with EGF (20 ng/ml) and bFGF (10 ng/ml) and labeled with BrdU (10 mg/ml) for 3 hr. Nes, nestin; Tuj, Tuj1; D, DAPI. Scale bars represent 50 mm. well as immortalized intestinal epithelial cells, prompted us to assess whether PLAGL2 influences the stem cell-like properties of human glioma cells. These stem-like properties are thought to reside in the GIC subpopulation, which manifest by their self-renewal, partial multi-lineage differentiation capacities, and superior tumorigenic potential in orthotopic models (Bao et al., 2006; Lee et al., 2006; Piccirillo et al., 2006; Singh et al., 2004; Son et al., 2009) . To assess such properties, we used early passage, patient-derived GICs that, under serum-free conditions, retain phenotypes and genotypes more closely mirroring primary tumor profiles as compared to serum-cultured established glioma cell lines that have largely lost their developmental identities (Galli et al., 2004; Lee et al., 2006; Pollard et al., 2009) .
Using the GIC model system, we observed that PLAGL2-transduced GICs (PLAGL2 GBM-1) versus vector-transduced GICs (control GBM-1) displayed a 4.3-fold increase (8.11% versus 1.89%) of CD133-positive subpopulation; CD133 is a surface progenitor marker associated with human GICs ( Figure 5A and Figure S5A ). Similar results were obtained in two other independently derived GIC lines ( Figures S5A and  S5B ). When cultured under differentiation-inducing conditions, PLAGL2-expressing GICs retained robust Nestin expression and substantially higher cell proliferation relative to the control cells as measured by a 1 hr BrdU incorporation assay (6.8 ± 2.5% versus 23.7 ± 6.7%; p = 0.003) (Figures 5B and 5C) . Moreover, the in vivo tumorigenic assay indicated that the PLAGL2-GICs (GBM-1) displayed enhanced tumorigenic potential. Compared to the control mice grafted intracranially with 5000 vector control GBM-1 that survived about 4 to 5 months ( Figure 5D ), the mice injected with PLAGL2-GBM-1 often developed diffusively infiltrating gliomas within 2 to 3 months and died at a median of 13.2 weeks. Notably, when examined at early time points after implantation, unlike vector control GICs that generated well circumscribed lesions with a clear boundary, the PLAGL2-GIC tumors were substantially more invasive with diffusively infiltrating tumor cells in the surrounding brain parenchyma ( Figure 5E ). These in vivo findings are consistent with the above in vitro Boyden chamber assay indicating that high PLAGL2 expression promotes glioma cell invasion. Conversely, shRNA-mediated silencing of endogenous PLAGL2 expression in a human GIC line (GBM-3) with relatively higher PLAGL2 expression substantially decreased its in vivo tumorigenicity ( Figure 5F and Figure S5C ). Together, these findings support the hypothesis that PLAGL2 functions to maintain stemness of the GICs in the context of differentiation cues and enhances their tumorigenicity and cellular invasion potential.
PLAGL2 Activates Wnt/b-Catenin Pathway in NSC/Progenitor Cells PLAGL2 is a Zinc finger transcription factor localized in the nucleus (Kas et al., 1998) . In an attempt to elucidate the molecular mechanisms underlying PlagL2's impact on murine p53 À/À NSC and human GIC differentiation, we performed transcriptome comparisons of PlagL2-transduced and vector control p53 À/À NSCs following the differentiation induction. As early as 24 hr after induction, approximately 400 genes exhibited significant differential expression. Ingenuity pathway analysis of the PlagL2-directed transcriptome identified ''cell-cycle G1/S checkpoint control'' as the most enriched canonical pathway ( Figure 6A ), consistent with the higher proliferation observed in the PlagL2-expressing NSCs and GICs under differentiation induction. Notably, the Wnt/b-catenin cascade emerged as the second most enriched canonical pathway. qRT-PCR further confirmed that mRNA transcripts of multiple Wnt pathway components, including the Wnt6 ligand and Fzd9 and Fzd2 receptors, were substantially upregulated in PlagL2-expressing NSCs ( Figure 6B ). Consistently, upregulation of Wnt6, Fzd9, and Fzd2 was also observed in PlagL2-expressing astrocytes as well as the primary GBM clinical sample (G328) with PLAGL2 amplification ( Figures S6A and S6B ). Wnt/b-catenin signaling plays an important role in maintaining stem cells of various lineages including NSC/progenitor cells, and aberrant activation of the Wnt/b-catenin pathway leads to deregulated growth and cancer (Chenn and Walsh, 2002; Clevers, 2006; Kalani et al., 2008) . Thus, our unbiased genome-scale analysis and confirmatory findings raised the possibility that PlagL2's function of suppressing NSC/progenitor cell differentiation might be mediated in part through activation of the Wnt/b-catenin pathway. A large body of previous work has established that the canonical Wnt signaling pathway executes its actions through the regulated degradation of the transcriptional coactivator b-catenin (Clevers, 2006; He et al., 2004; Logan and Nusse, 2004) . In the absence of Wnt stimulation, b-catenin is phosphorylated by GSK3 within the Axin complex and then targeted for rapid degradation by the proteasome (Aberle et al., 1997; Amit et al., 2002; Liu et al., 2002) . On the contrary, stimulation by Wnt inhibits b-catenin phosphorylation and promotes stability.
Consistent with PlagL2-induced activation of Wnt receptors and ligands in NSC/progenitor cells, immunofluorescence staining revealed a significantly increased b-catenin accumulation within the PlagL2-NSC/progenitor cells as compared to the vector control cells ( Figure 6C ). In parallel, immunohistochemistry shown is mean ± SD from two independent experiments with triplicates. *p < 0.001 by two-tail t test. See also Figure S6 .
analysis detected strong b-catenin staining in both malignant glioma patient samples with PLAGL2 amplification ( Figure 6D ) and the orthotopic transplants of PLAGL2-GICs ( Figure S6C ), reinforcing the role of PLAGL2 on Wnt/b-catenin pathway activation. Moreover, introduction of PlagL2 into murine NSC/progenitor cells and astrocytes enhanced their TCF-dependent TOPflash reporter activity ( Figure 6E and Figure S6D ). Similar results were observed using HEK293T and human glioma LN215 cells (Figures S6E and S6F) . Collectively, these data indicate that PLAGL2 can activate the canonical Wnt/b-catenin signaling cascade.
Inhibition of Wnt Signaling Attenuates PLAGL2's Activity on NSC/Progenitor Cell Differentiation
Numerous studies have documented the importance of Wnt proteins and its canonical signaling surrogates in the maintenance of stem cells in different tissues (Adachi et al., 2007; Chenn and Walsh, 2002; Grigoryan et al., 2008; Nusse, 2008; Pinto and Clevers, 2005; Zechner et al., 2003) . Aberrant activation of Wnt/b-catenin signaling tips the homeostatic balance toward pathological states including malignant transformation. Consistently, we found that introduction of a stabilized form of b-catenin into the mouse p53 À/À NSC/progenitor cells attenuates their differentiation capacity while enhancing proliferation ( Figure S7A ). This established paradigm, coupled with the above genomic analysis, prompted us to test whether PlagL2 acts through the Wnt/b-catenin pathway to maintain the progenitor state of normal and neoplastic stem cells under differentiationinducing conditions. We first investigated whether suppression of Wnt/b-catenin signaling through Dickkopf-1 (DKK1) can attenuate PlagL2's function on NSC/progenitor differentiation. DKK1 is a secreted Wnt inhibitor, which functions through direct binding to the Wnt coreceptor Lrp5/6 and thus disrupts Wnt-induced canonical Wnt/b-catenin pathway activation (Mao et al., 2001; Semenov et al., 2001 ). Since our data indicated that PlagL2 activates Wnt/b-catenin cascade on upstream signaling events through upregulating ligand and receptor expression, one would predict that introduction of DKK1 should suppress PlagL2-mediated Wnt pathway activation. Indeed, while enforced PlagL2 expression in NSC/progenitor cells significantly increased the TOPflash reporter activities as compared to the control cells, further cotransfection with DKK1 largely reversed the stimulatory effect of PlagL2 on the reporter activity ( Figures 7A) . Moreover, introduction of DKK1 into PlagL2-expressing NSC/progenitor cells partially restored their differentiation potential as demonstrated by the decreased progenitor marker (Nestin) staining, increased lineage marker (GFAP/Tuj1) expression, and reduced cell proliferation ( Figures 7B and 7C) . Similar results were obtained when shRNAs against Wnt6 or Fzd2 were introduced into PlagL2-expressing NSC/progenitor cells ( Figures 7D and 7E and Figure S7B ). ) and such disturbances are often driven by genomic aberrations in cancer cells. In the current study, integrative genomic and functional analyses led to the identification and validation of PLAGL2 as a potent oncoprotein frequently targeted for copy number gain/amplification in human malignant gliomas and colon cancers. Using both normal and neoplastic NSC/progenitor cells as model systems, we demonstrated that ectopic PLAGL2 expression greatly enhances NSC/progenitor cell self-renewal and proliferation upon differentiation induction, suggesting that PLAGL2 executes its oncogenic activities through regulating the state of cellular differentiation. Additionally, we have provided evidence that this function of PLAGL2 is at least partially attributable to its capacity to activate Wnt/b-catenin signaling.
It has become increasingly clear that many cancers are heterogeneous, reminiscent of normal tissue renewal with stem cells at the apex of this hierarchy. The identification of clonogenic tumor-initiating cells with stem-like features across many different tumor types has supported the existence of a cellular hierarchy in tumors (Al-Hajj et al., 2003; Bonnet and Dick, 1997; Hemmati et al., 2003; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004; Taylor et al., 2005) . These tumor-initiating cells represent a reservoir of self-sustaining cells with potent proliferative activity, differentiation resistance, and tumorigenic potential (Clarke et al., 2006; Dick, 2008; Gilbertson and Rich, 2007; Reya et al., 2001 ). Therefore, a relative arrest in differentiation, such as seen in the PLAGL2-overexpressing GICs, could contribute to malignant glioma progression through maintenance and expansion of the GIC pool under conditions that would otherwise lead to their differentiation. Alternatively, the differentiation-resistant state promoted by elevated PLAGL2 expression could potentially lead to the accrual of self-renewing glioma cells in which cell proliferation and differentiation are uncoupled and therefore will allow a plurality of glioma cells to assume indefinite proliferative capacity as suggested by the ''blocked differentiation'' model of cancer (Buick et al., 1979) . Support for this view derives from the observations that PLAGL2 overexpression leads to decreased astroglial differentiation, enhanced renewal in NSCs under differentiation induction conditions, increased CD133+ subpopulations, and enhanced GIC tumorigenicity in vivo.
We provide further evidence that enhanced PLAGL2 expression contributes to the progression of a subset of human malignant gliomas through regulating their differentiation and renewal. Unlike normal NSCs that undergo progressive differentiation along a developmental hierarchy into lineage-restricted progenitors and then their mature progenies (Alvarez-Buylla et al., 2001; Gage, 2000; Temple, 2001) , human malignant glioma cells generally show minimal terminal differentiation traits and instead exhibit robust expression of progenitor markers such as Nestin (Tohyama et al., 1992) . Furthermore, the self-renewal capacity of the isolated GICs tends to correlate with their tumor grade (Singh et al., 2003) , supporting the idea that ''differentiation arrest'' represents a common feature of malignant glioma progression. Like PLAGL2, some oncogenes can function to interfere with normal stem cell differentiation, MYC being a notable example, and such oncogenes also affect glioma cell differentiation (Ben-Porath et al., 2008; Bruggeman et al., 2007; Molofsky et al., 2003; Shachaf et al., 2004) . However, PLAGL2's function on differentiation does not appear to use the MYC axis as suggested by the minimal impact of PLAGL2 on MYC protein expression (data not shown), suggesting that multiple pathways can be commandeered to sustain self-renewal of GICs in the face of differentiation cues. Consistent with this notion, the BMP-BMPR signaling system that controls the activity of normal brain stem cells can function as a key inhibitory regulator of GICs by regulating their differentiation status (Bao et al., 2006; Calabrese et al., 2007; Hemmati et al., 2003; Lee et al., 2006; Piccirillo et al., 2006; Singh et al., 2004; Son et al., 2009 ). For example, dysregulated BMP pathway with epigenetically silenced BMP receptor 1B (BMPR1B) expression has been demonstrated to contribute to the tumorigenicity of a subset of malignant gliomas through blocking their GIC differentiation (Lee et al., 2008) . Forced BMPR1B expression in these GICs restored their differentiation potential and substantially decreased their tumorigenic potential, reinforcing further the view that targeting these differentiation control pathways may provide novel treatment avenues for malignant gliomas.
The canonical Wnt cascade is a critical regulator of stem cell renewal and differentiation in many tissues (Clevers, 2006; Nusse, 2008; Reya and Clevers, 2005) . During normal brain development, Wnt signaling is required for controlling the size of the self-renewing NSC/progenitor population (Kalani et al., 2008) . Moreover, while attenuation of Wnt signaling causes a reduction in the NSC/progenitor compartment, its activation through b-catenin can increase the cycling and expansion of neural precursors (Chenn and Walsh, 2002; Zechner et al., 2003) , raising the possibility that abnormal Wnt pathway activation may promote NSC/progenitor transformation. Indeed, uncontrolled Wnt pathway activation through mutations in APC (Huang et al., 2000) , b-catenin (Zurawel et al., 1998) , or axin (Baeza et al., 2003; Dahmen et al., 2001) has been found in a subgroup of medulloblastomas, a pediatric brain tumor in the cerebellum. Although these specific mutations appear to be rare in gliomas, the level of b-catenin expression appears to be related to the histological grade in a subset of gliomas (Utsuki et al., 2002) . Sustained b-catenin activation independent of the mutations has also been demonstrated in a subset of breast, ovarian, and pancreatic cancers (Bafico et al., 2004; Wang et al., 2009) . In the present study, our findings that PLAGL2 functions to activate Wnt/b-catenin pathway while repression of Wnt activation in PLAGL2-expressing NSCs sensitize them to differentiation further support Wnt signaling as a key contributor to the malignant behavior of at least a subset of malignant gliomas. Overall, these data support a model in which PLAGL2 functions primarily to affect gliomagenesis via its impact on differentiation and self-renewal (Figure 8 ). In the unstimulated NSC/progenitor cells lacking PLAGL2 overexpression, the Wnt receptor complexes are not bound by ligands, allowing the axin/APC/GSK3b complex to phosphorylate b-catenin and target it for rapid degradation. When abnormally overexpressed, PLAGL2 activates Wnt ligand and receptor transcription, resulting in the disruption of the axin/APC/GSK3b complex, b-catenin stabilization, and its subsequent activation. The activated b-catenin is then transferred into the nucleus and activates its downstream effectors, which functionally contribute to PLAGL2-mediated differentiation arrest and self-renewal maintenance under differentiation induction. However, it is worth noting that attenuation of Wnt signaling in PlagL2-expressing NSCs through either DKK1 overexpression ( Figures 7B and 7C ) or Wnt6/Fzd2 knockdown ( Figures 7D and 7E ) only partially reverses PlagL2-mediated NSC/progenitor differentiation suppression, suggesting that the combined actions of PLAGL2 at multiple points in the pathway are needed for full effort and/or that other differentiation/renewal pathways contribute to regulation of differentiation processes in gliomas.
In summary, aberrant expression of PLAGL2 can function to sustain normal and neoplastic NSC/progenitor cell renewal and proliferation under differentiation induction conditions, findings consistent with the prevailing view that differentiation induction restrains tumor cell self-renewal and tumorigenic potential (Pierce and Speers, 1988) . Indeed, the differentiation therapy has contributed significantly to the management of leukemia (Wang and Chen, 2008) . In this regard, one would predict that a more detailed understanding of the pathways governing self- renewal and/or differentiation of NSCs and, by extension, GICs would provide productive entry points for novel drug development efforts in malignant gliomas and other cancer types.
EXPERIMENTAL PROCEDURES Cell Lines and Human Samples
The human glioma cell lines LN215, LN229, A172, Hs683, LN319, LN340, LNZ308, SF767, U87, and U343 and the human embryonic kidney cell line HEK293T were purchased from American Type Culture Collection. Frozen tumor specimens and human GIC lines were obtained from the Memorial Sloan-Kettering Cancer Center tumor bank. All tumor specimens were collected after obtaining written informed consent preoperatively. This study was approved by the Institutional Review Boards of the Memorial Sloan-Kettering Cancer Center and Dana-Farber Cancer Institute. The GICs were generated as described previously (Bao et al., 2006; Lee et al., 2006; Piccirillo et al., 2006; Singh et al., 2004 ) without sorting and maintained as tumor spheres using low-attachment plates in NeuroCult NS-A proliferation media (human; Stem Cell Technologies) with growth factors. The common genomic and genetic mutations of the human glioma cell lines and GICs are included in Table S1 .
Mice and Orthotopic Transplants Primary murine p53
À/À and Ink4a/Arf À/À Pten À/À astrocytes were isolated from 5-day-old pups as previously described (Bachoo et al., 2002) and maintained in DMEM containing 10% FBS. Primary murine wild-type, p53
, and Ink4a/Arf À/À Pten À/À NSCs were isolated from the SVZ regions of 1-monthold mice as previously described (Rietze and Reynolds, 2006; Zheng et al., 2008) and maintained in NeuroCult NS-A proliferation media (mouse; Stem Cell Technologies) with growth factors. The orthotopic transplantation was performed as previously described . Animals were followed daily for development of neurological deficits. All mice experiments were performed with the approval of the Harvard and Dana-Farber Cancer Institute Institutional Animal Care and Use Committee.
Antibodies for Immunofluorescence, Immunohistochemistry, and Western Blot Analysis
The following antibodies were used: GFAP (Dako and BD Biosciences), human nestin, mouse nestin (Chemicon), Tuj-1 (Covance), S-100 (Lab Vision), PS-Smad1/5/8, Smad1 (Cell Signaling), CD133 (Miltenyi Biotech), BrdU (Abcam), HA (Covance), b-catenin, b-actin (Santa Cruz Biotechnology), and EGFR (Upstate).
Immunostaining
Cells were seeded on polyornithine (Sigma-Aldrich)-and fibronectin (SigmaAldrich)-coated coverslips and cultured within the indicated media. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 in PBS and blocked with 1% BSA. Subsequently, samples were incubated with indicated primary antibodies overnight at 4 C and corresponding Alexa Fluor-conjugated secondary antibodies (Invitrogen) 1 hr at room temperature and mounted with mounting medium with DAPI (Vector). Microscopic images were obtained with a Zeiss LSM 510 confocal microscope in the Harvard NeuroDiscovery Center optical imaging core, using constant exposure times for each channel in individual experiments.
Cell Invasion and Anchorage-Independent Growth Assays
Cell invasion assays were performed in duplicate or triplicate in a Boyden chamber of 24 well inserts coated with matrix proteins as per the manufacturer's protocol (BD Biosciences). Cells (2 3 10 5 ) were washed and then seeded in serum-free DMEM (Invitrogen). The chemoattractant used was DMEM + 10% FBS. After 18 hr incubation and removal of the noninvading cells, the chambers were stained with 0.5% Crystal Violet (Sigma-Aldrich) for 20 min and the invading cells were counted. Anchorage-independent growth assays were performed in duplicate or triplicate in 6 well plates. 10 4 of indicated cells per well were seeded in DMEM + 10% FBS containing 0.4% low-melting agarose on the top of bottom agar containing 1% lowmelting agarose DMEM + 10% FBS. After 14-21 days, colonies were stained with iodonitrotetrazoliumchloride (Sigma-Aldrich) and counted.
NSC Self-Renewal Assay NSC self-renewal capacity was measured by plating 100 cells/ml into 6 or 12 well ultra-low cluster plates in NSC proliferation media containing growth factors (EGF 20 ng/ml and bFGF 10 ng/ml; Sigma-Aldrich) with or without BMP2 (50 ng/ml; R&D Systems). The number of neurospheres that formed subsequently per well was quantified after 8 (no BMP2) or 14 days (with BMP2) and relative sphere formation was plotted versus indicated control.
Expression Profiling and Ingenuity Pathway Analysis mRNA expression profiling was performed at the Dana-Farber Microarray Core facility using the Mouse Genome 430 2.0 Array (Affymetrix). Student's t test was used to identify differentially expressed genes according to expression profiles. The ingenuity pathway analysis application was performed to identify canonical pathways that were most significant to the functionally related genes according to the manufacturer's instruction (Ingenuity Systems). In brief, differentially expressed genes with threshold p % 0.05 were mapped into Ingenuity Pathways Analysis database as input. Complete profiles are deposited on the GEO website under super series accession number GSE21143.
Statistical Analysis
Tumor-free survivals were analyzed using Graphpad Prism4. Statistical analyses were performed using nonparametric Mann-Whitney test. Comparisons of cell growth, self-renewal, and differentiation were performed using the unpaired Student's t test. For all experiments with error bars, standard deviation was calculated to indicate the variation within each experiment and data, and values represent mean ± SEM.
shRNA Sequences See Supplemental Experimental Procedures for siRNA and shRNA sequences.
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